‘Public-private’ deal heralds revolution in search for new drug treatments

GlaxoSmithKline and non-profit institutes hope to fast-track research into cures using patient DNA

Science Editor

Britain’s biggest drug company has signed a pioneering deal with two public research institutes to develop new medicines based on patient DNA in the hope of discovering lucrative treatments for a range of illnesses with a genetic basis, from cancer to heart disease.

GlaxoSmithKline (GSK) has promised to publicly release any early research findings for free in return for the expertise and help offered by the Wellcome Trust Sanger Institute, where the human genome was decoded, and the European Bioinformatics Institute (EBI), both based on the same campus in Cambridge.

The aim of the unique collaboration is to identify potential targets in the body for new drugs based on an analysis of the huge volumes of data generated by the human genome and similar studies into complex biological molecules such as proteins and peptides.

In return for its investment, GSK hopes to steal a march on its competitors by identifying targets early enough for it to develop drugs that have less risk of failure at the early stages of clinical trials, said Ewan Birney, associate director of the EBI and the interim head of the new Centre for Therapeutic Target Validation.

“This is about enlightened self-interest. They are funding public research to do the groundwork in the earliest stage of drug discovery. They really want to change the game for this early part of the drug-discovery process,” Dr Birney said.

“They are backing themselves that they can do the next phase and find the right drug that works better than anyone else. They realised that some things are better solved in the public domain,” he said.

One of the preconditions of the collaboration is that the research findings will be freely available, but GSK can direct the research towards areas where the company already has a commercial interest, Dr Birney said.

It is estimated that about nine out of 10 potential new drugs fail when they enter clinical trials even though they have shown promise in the laboratory and in animal trials. 

Another problem is that even many licensed drugs do not work on all potential patients - some people do not respond because of their genetic makeup. It is one of the best-kept secrets of the pharmaceuticals industry that most of the drugs it makes do not work on most of the patients they are designed for.

“We are interested in knowing the proteins to target for drugs. In the case of responders and non-responders, were interested really in the new proteins in the non-responders which look like the right ones to target,” Dr Birney said.

The Sanger Institute is a world leader in decoding and analysing genome data while the EBI’s area of expertise is handling the huge volume of data generated by genome science, as well as new research in proteomics (proteins science), biochemistry and the biological basis of disease.

The centre will be built on the same site in Cambridge where the Sanger Institute is based and will initially employ about 50 researchers.

Patrick Vallance, president of pharmaceuticals research and development at GSK, said that by changing its business model and sharing information in a collaborative way, the company hopes to accelerate the development of new medicines.

“Target validation is one of the greatest challenges in drug discovery. We need to understand better the mechanisms in our body related to disease to improve how we can develop the most effective mechanisms,” Dr Vallance said.

Professor Sir Mike Stratton, director of the Sanger Institute, said: “Advances in genomics have led to a rapid increase in the availability of drug targets, providing enormous opportunity but also posing the problem of how we best convert this knowledge into medicines.

“The challenge we now address it to identify those new targets with the greatest relevance to human disease which, in turn, will undoubtedly increase the speed and efficiency in which new medicines can be developed.”

Start your day with The Independent, sign up for daily news emails
News
Professor David Nutt wants to change the way gravely ill patients are treated in Britain
people Why does a former Government tsar believe that mind-altering drugs have a place on prescription?
News
Norway’s ‘The Nordland Line – Minute by Minute, Season by Season’ continues the trend of slow TV
television The BBC have commissioned a series of programmes doing away with high-production values, commentary, script or drama
Arts and Entertainment
art
Sport
Jonny Evans has pleaded not guilty to an FA charge for spitting at Papiss Cisse
football
ebooks
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Ashdown Group: Technical Presales Consultant - London - £65,000 OTE.

£65000 per annum: Ashdown Group: Technical Presales Engineer - central London ...

Recruitment Genius: Physiotherapist / Sports Therapist

£20000 - £50000 per annum: Recruitment Genius: A Physiotherapist / Sports Ther...

Recruitment Genius: Sales Executive / Advisor

£8 - £9 per hour: Recruitment Genius: Sales Executives / Advisors are required...

Recruitment Genius: Warehouse Operative

£14000 - £15000 per annum: Recruitment Genius: An opportunity has arisen for a...

Day In a Page

Homeless Veterans campaign: Donations hit record-breaking £1m target after £300,000 gift from Lloyds Bank

Homeless Veterans campaign

Donations hit record-breaking £1m target after huge gift from Lloyds Bank
Flight MH370 a year on: Lost without a trace – but the search goes on

Lost without a trace

But, a year on, the search continues for Flight MH370
Germany's spymasters left red-faced after thieves break into brand new secret service HQ and steal taps

Germany's spy HQ springs a leak

Thieves break into new €1.5bn complex... to steal taps
International Women's Day 2015: Celebrating the whirlwind wit of Simone de Beauvoir

Whirlwind wit of Simone de Beauvoir

Simone de Beauvoir's seminal feminist polemic, 'The Second Sex', has been published in short-form for International Women's Day
Mark Zuckerberg’s hiring policy might suit him – but it wouldn’t work for me

Mark Zuckerberg’s hiring policy might suit him – but it wouldn’t work for me

Why would I want to employ someone I’d be happy to have as my boss, asks Simon Kelner
Confessions of a planespotter: With three Britons under arrest in the UAE, the perils have never been more apparent

Confessions of a planespotter

With three Britons under arrest in the UAE, the perils have never been more apparent. Sam Masters explains the appeal
Russia's gulag museum 'makes no mention' of Stalin's atrocities

Russia's gulag museum

Ministry of Culture-run site 'makes no mention' of Stalin's atrocities
The big fresh food con: Alarming truth behind the chocolate muffin that won't decay

The big fresh food con

Joanna Blythman reveals the alarming truth behind the chocolate muffin that won't decay
Virginia Ironside was my landlady: What is it like to live with an agony aunt on call 24/7?

Virginia Ironside was my landlady

Tim Willis reveals what it's like to live with an agony aunt on call 24/7
Paris Fashion Week 2015: The wit and wisdom of Manish Arora's exercise in high camp

Paris Fashion Week 2015

The wit and wisdom of Manish Arora's exercise in high camp
8 best workout DVDs

8 best workout DVDs

If your 'New Year new you' regime hasn’t lasted beyond February, why not try working out from home?
Paul Scholes column: I don't believe Jonny Evans was spitting at Papiss Cissé. It was a reflex. But what the Newcastle striker did next was horrible

Paul Scholes column

I don't believe Evans was spitting at Cissé. It was a reflex. But what the Newcastle striker did next was horrible
Miguel Layun interview: From the Azteca to Vicarage Road with a million followers

From the Azteca to Vicarage Road with a million followers

Miguel Layun is a star in Mexico where he was criticised for leaving to join Watford. But he says he sees the bigger picture
Frank Warren column: Amir Khan ready to meet winner of Floyd Mayweather v Manny Pacquiao

Khan ready to meet winner of Mayweather v Pacquiao

The Bolton fighter is unlikely to take on Kell Brook with two superstar opponents on the horizon, says Frank Warren
War with Isis: Iraq's government fights to win back Tikrit from militants - but then what?

Baghdad fights to win back Tikrit from Isis – but then what?

Patrick Cockburn reports from Kirkuk on a conflict which sectarianism has made intractable